Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    TriVerity is intended to be used in emergency department settings in patients with suspected acute infection and sepsis to assess the likelihood of a bacterial infection, a viral infection, and risk of acute decompensation.
    By Global Biodefense StaffNovember 15, 2023
    Credit: Inflammatix
    Share
    Facebook LinkedIn Reddit Email

    Inflammatix, Inc., a molecular diagnostics company, today announced an important milestone with the completion of technical development for its TriVerity Acute Infection and Sepsis Test System.

    The system is comprised of the company’s Myrna Instrument and the TriVerity Cartridge. The Myrna Instrument is capable of sample-to-answer quantitation of up to 64 messenger RNAs (mRNAs) from whole blood or other sample types in about 30 minutes. It is designed to be Clinical Laboratory Improvement Amendments (CLIA)-waivable to enable point-of-care deployments. The disposable TriVerity Cartridges are expected to be room-temperature stable for up to 12 months.

    The TriVerity Acute Infection and Sepsis Test, Inflammatix’s lead product, incorporates a panel of 29 mRNAs to “read” the body’s immune response and thus aid in the diagnosis of patients with suspected acute infection and sepsis. It is designed to potentially facilitate diagnosis of patients with suspected infection that present in US emergency departments.

    “Myrna will be the world’s highest-multiplex point-of-care system capable of quantitating RNA, allowing us to bring ‘precision medicine’ into acute care settings,” said Dr. Timothy Sweeney, CEO and co-founder of Inflammatix. “Completing technical development brings TriVerity a step closer to FDA submission and launch, and enables us to execute key clinical studies.”

    The company has resumed completion of its clinical studies, including its SEPSIS-SHIELD study (NCT04094818) required for submission of the TriVerity Test system to the U.S. Food and Drug Administration (FDA). The multi-center study has already enrolled 955 of the estimated 1,500 patients needed. Inflammatix estimates study completion and FDA submission to occur by spring 2024.

    Inflammatix product development has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA). The TriVerity Acute Infection and Sepsis Test System is a product in development, is not currently for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

    READ ALSO

    Bringing Value to the Care Pathway: The Rising Role of Rapid Diagnostics. CIDRAP-ASP

    Lessons learned from the deadly combination of sepsis and Covid-19. STAT

    Transforming How We Think About Sepsis. Global Biodefense

    Disaster Medicine: New Resource Prepares for Sepsis Encountered in Austere Conditions. Global Biodefense

    BARDA Hospital Preparedness Patient Triage POC Diagnostics Rapid Diagnostics Sepsis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleVirginia Tech Lab Selected for National Partnership to Fight Emerging Diseases
    Next Article Valley Fever: An Invisible Killer Expands Its Range in the American West

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    Novavax’s Prototype COVID-19 Vaccine Nuvaxovid Receives Full Approval in Singapore

    October 18, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.